BMC Infectious Diseases (Apr 2021)

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

  • Machiko Umemura,
  • Goki Suda,
  • Shihori Tsukamoto,
  • Ko Ebata,
  • Shinjiro Takahash,
  • Takashi Sasaki,
  • Sae Nakajima,
  • Koji Hirata,
  • Mariko Ozasa,
  • Masatoshi Takano,
  • Masaki Katagiri,
  • Naoya Sakamoto

DOI
https://doi.org/10.1186/s12879-021-06091-x
Journal volume & issue
Vol. 21, no. 1
pp. 1 – 5

Abstract

Read online

Abstract Background In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies. Case presentation We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24 weeks after glecaprevir and pibrentasvir completion. Conclusion On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.

Keywords